After-hours movers:

ON Semiconductor (NASDAQ: ON) fell 7% after guidance disappointed investors. The company sees Q1 2026 revenue of $1.44-1.54 billion, versus the consensus of $1.51 billion

Credo Technology (NASDAQ: CRDO) rose 14% after preliminary quarterly revenue beat estimates. Credo expects to report third quarter revenue between $404 million and $408 million, surpassing the high end of its previously announced guidance range of $335 million to $345 million.

Upwork (NASDAQ: UPWK) fell 20% despite ok quarterly figures after guidance missed estimates. Upwork sees Q1 2026 revenue of $192-197 million, versus the consensus of $200.5 million.

Goodyear Tire (NASDAQ: GT) fell 7% after EPS missed estimates, despite a top line beat.

Amkor Technology (NASDAQ: AMKR) rose 2% after results topped consensus. Revenue for the quarter came in at $1.89 billion versus the consensus estimate of $1.84 billion.

Regenxbio (NASDAQ: RGNX) fell 27% after it announced that the U.S. Food and Drug Administration issued a Complete Response Letter rejecting its biologics license application for RGX-121, a gene therapy for treating Mucopolysaccharidosis II, also known as Hunter syndrome.

Medpace Holdings (NASDAQ: MEDP) fell 6% despite quarterly revenue that beat estimates, after it guidance was viewed as disappointing. Medpace Holdings sees FY2026 revenue of $2.76-2.86 billion, versus the consensus of $2.81 billion.